#Spain #Barcelona #B Corporation #ESTEVE #Pharma Expansion

ESTEVE's Global Expansion and Transformational Growth

In a remarkable move towards becoming a global healthcare leader, ESTEVE has released its results for 2025, showcasing a year filled with robust strategic execution and impressive growth. The company achieved a notable 14% increase in net revenues, with its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rising by 19% compared to 2024. These figures not only reflect ESTEVE's successful business strategies but also its deep-rooted commitment to social and environmental governance (ESG).

Throughout 2025, ESTEVE remained steadfast in its long-term goal of establishing itself as a global entity, blending organic growth within its pharmaceutical sector with the addition of highly specialized medicines. This proactive approach has led to a significant enhancement of its portfolio, introducing eight new products in recent months alone.

The company further escalated its Contract Development and Manufacturing Organization (CDMO) services by acquiring new assets in the USA, pushing its capabilities forward and allowing it to cater to a broader range of pharmaceutical demands. This strategic move has not only reinforced ESTEVE's competitive edge but has also catered to the increasing need for early development services in the rapidly evolving pharmaceutical landscape.

With the closure of the acquisition of TerSera’s Infusion Business Unit in March 2026, ESTEVE gained access to two highly specialized medications, reflecting its ability to integrate new assets effectively. Across the past 18 months, the company has succeeded in integrating a total of eight new products, enhancing its capacity to serve underserved patient populations, particularly in oncology and endocrinology.

The CEO of ESTEVE, Staffan Schüberg, emphasized, “Our sustained double-digit growth and robust margins in 2025 symbolize the strength of our dual-engine business model. Through our investments in innovation and our focus on combining social responsibility with healthcare needs, we continue to deliver valuable solutions for patients while ensuring profitable growth.”

The financial outcomes for ESTEVE paint a picture of sustained health for the company, achieving revenues of €828 million in 2025, with a comparable rate of growth across both the pharma and CDMO sectors. The reported EBITDA stood at €151 million, maintaining a healthy margin of 18%, showcasing the company's ability to manage and expand its diversified business model effectively.

In response to the growing demand and to cultivate long-term growth, ESTEVE made significant investments in product development and technological advancement, amounting to €49 million in 2025. The company also allocated €104 million primarily for ongoing construction of CDMO facilities in both Spain and China as part of its broader strategy.

Commitment to Sustainability and Social Responsibility

Moreover, ESTEVE has recently achieved B Corporation Certification, a landmark accomplishment that affirms its commitment to high standards of social and environmental performance. This certification not only highlights the company's operational integrity but reinforces its dedication to operating responsibly within the global healthcare framework.

Throughout its operations, ESTEVE has embedded sustainability as a core principle, integrating ESG criteria into decision-making processes at every level. This year, the company launched a unified ESG strategy, progressed on its pathway to Net Zero, and implemented strategies to significantly reduce its environmental impact through renewable energy initiatives and efficient resource management.

With over 2,200 employees representing 35 different nationalities, ESTEVE closed 2025 with record engagement levels at 87%, reflecting a strong organizational culture driven by the core values of accountability, transparency, and the prioritization of people.

Moving forward, ESTEVE has set its sights on achieving €1 billion in net revenue by 2027, in part by honing in on both organic and inorganic expansion strategies within its pharmaceutical and CDMO segments. The company’s ambitious yet calculated plans are paving the way for a brighter future in global healthcare delivery.

About ESTEVE

Established in 1929 and headquartered in Barcelona, ESTEVE has emerged as a key player in the international healthcare landscape. Through its focused initiatives, ESTEVE aims to improve lives collectively by offering innovative solutions tailored for individuals with complex diseases. The company's dual role in both the pharmaceutical and manufacturing sectors underscores its commitment to advancing healthcare and ensuring broad access to essential medications.